Literature DB >> 11898866

Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence.

R J Reiter1, D X Tan, L C Manchester, W Qi.   

Abstract

Melatonin (N-acetyl-5-methoxytryptamine), an endogenously produced indole found throughout the animal kingdom, was recently reported, using a variety of techniques, to be a scavenger of a number of reactive oxygen and reactive nitrogen species both in vitro and in vivo. Initially, melatonin was discovered to directly scavenge the high toxic hydroxyl radical (*OH). The methods used to prove the interaction of melatonin with the *OH included the generation of the radical using Fenton reagents or the ultraviolet photolysis of hydrogen peroxide (H202) with the use of spin-trapping agents, followed by electron spin resonance (ESR) spectroscopy, pulse radiolysis followed by ESR, and several spectrofluorometric and chemical (salicylate trapping in vivo) methodologies. One product of the reaction of melatonin with the *OH was identified as cyclic 3-hydroxymelatonin (3-OHM) using high-performance liquid chromatography with electrochemical (HPLC-EC) detection, electron ionization mass spectrometry (EIMS), proton nuclear magnetic resonance (1H NMR) and COSY 1H NMR. Cyclic 3-OHM appears in the urine of humans and other mammals and in rat urine its concentration increases when melatonin is given exogenously or after an imposed oxidative stress (exposure to ionizing radiation). Urinary cyclic 3-OHM levels are believed to be a biomarker (footprint molecule) of in vivo *OH production and its scavenging by melatonin. Although the data are less complete, besides the *OH, melatonin in cell-free systems has been shown to directly scavenge H2O2, singlet oxygen (1O2) and nitric oxide (NO*), with little or no ability to scavenge the superoxide anion radical (O2*-) In vitro, melatonin also directly detoxifies the peroxynitrite anion (ONOO-) and/or peroxynitrous acid (ONOOH), or the activated form of this molecule, ONOOH*; the product of the latter interaction is proposed to be 6-OHM. How these in vitro findings relate to the in vivo antioxidant actions of melatonin remains to be established. The ability of melatonin to scavenge the lipid peroxyl radical (LOO*) is debated. The weight of the evidence is that melatonin is probably not a classic chain-breaking antioxidant, since its ability to scavenge the LOO* seems weak. Its ability to reduce lipid peroxidation may stem from its function as a preventive antioxidant (scavenging initiating radicals), or yet unidentified actions. In sum, in vitro melatonin acts as a direct free radical scavenger with the ability to detoxify both reactive oxygen and reactive nitrogen species; in vivo, it is an effective pharmacological agent in reducing oxidative damage under conditions in which excessive free radical generation is believed to be involved.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898866     DOI: 10.1385/CBB:34:2:237

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  131 in total

1.  The Effect of Melatonin on Behavioral, Molecular, and Histopathological Changes in Cuprizone Model of Demyelination.

Authors:  Gelareh Vakilzadeh; Fariba Khodagholi; Tahereh Ghadiri; Amir Ghaemi; Farshid Noorbakhsh; Mohammad Sharifzadeh; Ali Gorji
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

2.  Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.

Authors:  Mmalebuso L Mokoena; Brian H Harvey; Francois Viljoen; Susanna M Ellis; Christiaan B Brink
Journal:  Psychopharmacology (Berl)       Date:  2015-04-17       Impact factor: 4.530

3.  The effects of exogenous melatonin on the morphology of thyrocytes in pinealectomized and irradiated rats.

Authors:  Z Kundurovic; E Sofic
Journal:  J Neural Transm (Vienna)       Date:  2006-01       Impact factor: 3.575

4.  Influence of melatonin and acetylsalicylic acid on lipid peroxidation and antioxidant enzyme activities in gastric mucosa.

Authors:  Tetsuya Mine
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

5.  Effects of melatonin or acetylsalicylic acid on gastric oxidative stress after bile duct ligation in rats.

Authors:  Alaaddin Polat; Memet Hanifi Emre
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

6.  Treatment with Isorhamnetin Protects the Brain Against Ischemic Injury in Mice.

Authors:  Jin-Jing Zhao; Jin-Qing Song; Shu-Yi Pan; Kai Wang
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

Review 7.  Disturbance of redox homeostasis as a contributing underlying pathomechanism of brain and liver alterations in 3-hydroxy-3-methylglutaryl-CoA lyase deficiency.

Authors:  Guilhian Leipnitz; Carmen Regla Vargas; Moacir Wajner
Journal:  J Inherit Metab Dis       Date:  2015-06-04       Impact factor: 4.982

8.  α-Ketoadipic Acid and α-Aminoadipic Acid Cause Disturbance of Glutamatergic Neurotransmission and Induction of Oxidative Stress In Vitro in Brain of Adolescent Rats.

Authors:  Janaína Camacho da Silva; Alexandre Umpierrez Amaral; Cristiane Cecatto; Alessandro Wajner; Kálita Dos Santos Godoy; Rafael Teixeira Ribeiro; Aline de Mello Gonçalves; Ângela Zanatta; Mateus Struecker da Rosa; Samanta Oliveira Loureiro; Carmen Regla Vargas; Guilhian Leipnitz; Diogo Onofre Gomes de Souza; Moacir Wajner
Journal:  Neurotox Res       Date:  2017-04-20       Impact factor: 3.911

9.  Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients.

Authors:  Richard Rosen; Dan-Ning Hu; Violete Perez; Katy Tai; Guo-Pei Yu; Min Chen; Paul Tone; Steven A McCormick; Joseph Walsh
Journal:  Mol Vis       Date:  2009-08-21       Impact factor: 2.367

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.